A Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of HTL0009936 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
Price : $35 *
At a glance
- Drugs HTL 9936 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; First in man
- Sponsors Heptares Therapeutics
- 17 Jun 2015 Results published in Heptares Therapeutics media release.
- 11 Jun 2015 Planned End Date changed from 1 Jun 2015 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 11 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2014 as reported by ClinicalTrials.gov.